China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment and dosing of all subjects in a Phase II clinical study for its ReCOV, a recombinant protein COVID-19 vaccine, with Pfizer’s mRNA vaccine Comirnaty as a control. The study, approved in the Philippines on August 3, has enrolled 600 subjects who will receive safety and immunogenicity follow-up upon immunization.
Vaccine Overview
ReCOV, developed by Recbio using new adjuvant and protein engineering platforms, has demonstrated good cross-neutralization effects and immune persistence against Omicron, Delta, and other strains. The vaccine features overall safety, scalability, low production cost, and good preparation stability, and can be stored and transported at room temperature.-Fineline Info & Tech
